Edwards RJ - Search Results

1

Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans.

Edwards RJ, Adams DA, Watts PS, Davies DS, Boobis AR. Edwards RJ, et al. Biochem Pharmacol. 1998 Aug 1;56(3):377-87. doi: 10.1016/s0006-2952(98)00033-1. Biochem Pharmacol. 1998. PMID: 9744576

2

Affinity and potency of proinhibitory antipeptide antibodies against CYP2D6 is enhanced using cyclic peptides as immunogens.

Schulz-Utermoehl T, Edwards RJ, Boobis AR. Schulz-Utermoehl T, et al. Among authors: edwards rj. Drug Metab Dispos. 2000 May;28(5):544-51. Drug Metab Dispos. 2000. PMID: 10772633

3

Identification of surface regions of cytochromes P-450 using anti-peptide antibodies.

Edwards RJ, Murray BP, Singleton AM, Davies DS, Boobis AR. Edwards RJ, et al. Biochem Soc Trans. 1989 Dec;17(6):1022-3. doi: 10.1042/bst0171022. Biochem Soc Trans. 1989. PMID: 2628055 No abstract available.

4

Interaction of the transactivating protein HIV-1 tat with sulphated polysaccharides.

Watson K, Gooderham NJ, Davies DS, Edwards RJ. Watson K, et al. Among authors: edwards rj. Biochem Pharmacol. 1999 Apr 1;57(7):775-83. doi: 10.1016/s0006-2952(98)00352-9. Biochem Pharmacol. 1999. PMID: 10075083

5

HIV-1-trans-activating (Tat) protein: both a target and a tool in therapeutic approaches.

Watson K, Edwards RJ. Watson K, et al. Among authors: edwards rj. Biochem Pharmacol. 1999 Nov 15;58(10):1521-8. doi: 10.1016/s0006-2952(99)00209-9. Biochem Pharmacol. 1999. PMID: 10535742 Review.

6

Reduced hepatic expression of CYP7A1 and CYP2C13 in rats with spontaneous hyperlipidaemia.

Brassil PJ, Debri K, Nakura H, Kobayashi S, Davies DS, Edwards RJ. Brassil PJ, et al. Among authors: edwards rj. Biochem Pharmacol. 1998 Jul 15;56(2):253-7. doi: 10.1016/s0006-2952(98)00015-x. Biochem Pharmacol. 1998. PMID: 9698080

7

Heterocyclic amines: evaluation of their role in diet associated human cancer.

Gooderham NJ, Murray S, Lynch AM, Edwards RJ, Yadollahi-Farsani M, Bratt C, Rich KJ, Zhao K, Murray BP, Bhadresa S, Crosbie SJ, Boobis AR, Davies DS. Gooderham NJ, et al. Among authors: edwards rj. Br J Clin Pharmacol. 1996 Jul;42(1):91-8. doi: 10.1046/j.1365-2125.1996.37513.x. Br J Clin Pharmacol. 1996. PMID: 8807149 Free PMC article. Review.

8

Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human.

Edwards RJ, Murray BP, Murray S, Schulz T, Neubert D, Gant TW, Thorgeirsson SS, Boobis AR, Davies DS. Edwards RJ, et al. Carcinogenesis. 1994 May;15(5):829-36. doi: 10.1093/carcin/15.5.829. Carcinogenesis. 1994. PMID: 8200083

9

Ontogenetic development of the distribution of constitutive and 3-methylcholanthrene-induced CYP1A1 and CYP1A2 in rabbit liver.

Rich KJ, Foster JR, Edwards RJ, Davies DS, Boobis AR. Rich KJ, et al. Among authors: edwards rj. J Histochem Cytochem. 1993 Jun;41(6):915-25. doi: 10.1177/41.6.8315282. J Histochem Cytochem. 1993. PMID: 8315282

10

Short synthetic peptides exploited for reliable and specific targeting of antibodies to the C-termini of cytochrome P450 enzymes.

Edwards RJ, Singleton AM, Murray BP, Davies DS, Boobis AR. Edwards RJ, et al. Biochem Pharmacol. 1995 Jan 6;49(1):39-47. doi: 10.1016/0006-2952(94)00395-3. Biochem Pharmacol. 1995. PMID: 7840781

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results